Tag Archives: Jack B. Jewett

angel

Bioscience innovators will pitch at White Hat Investors

Bioindustry Associations from across the Rocky Mountain Southwest Region are coming together to present an opportunity for Angels, Venture Capitalists and Strategic Investors to connect with the biotech and healthcare investment opportunities from across the Rocky Mountain Southwest states at White Hat Investors 2014 in Phoenix, Arizona on September 17 and 18, 2014.

“The West was won by innovators, investors, and prospectors who understood the value of discovery and accepted the challenge of investing in new frontiers,” shared Joan Koerber-Walker, president and CEO of the Arizona Bioindustry Association (AZBio). “Now, industry leaders and accredited investors have the opportunity to meet a new generation of biotech and healthcare pioneers at White Hat 2014, the first annual biotech and healthcare investor conference that showcases the best of the Rocky Mountain Southwest Region.”

White Hat Presenting Companies were selected from the region’s emerging innovation leaders in the fields of Diagnostics, Therapeutics, Medical Devices, and Health IT. Presenting companies are developing lifesaving and life improving innovations that will benefit people today and for generations to come while addressing some of our greatest health challenges including cancer, cardiovascular and pulmonary disease, neurological disorders, infectious disease, and more.

On September 17th, over 400 life science industry leaders will gather to view a company showcase, browse a student discovery zone and listen to presentations from local life science entrepreneurs on the BioAccel Best of the Best Stage from 3:00 p.m. – 6:00 p.m. in the North Ballroom of the Phoenix Convention Center. Free and open to the general public, it presents an opportunity for members of the community to connect with the region’s fastest growing innovation sector. The public pre-event will be followed at 6:00 p.m. by the AZBio Awards gala (registration required) honoring life science pioneer Roy Curtiss, III, PhD; Charles Arntzen, PhD, the Arizona State University Researcher who, with his team, played a key role in the development of ZMAPP, the experimental Ebola drug given to two health workers who were sickened by the deadly virus earlier this year; W.J. “Jim” Lane, Mayor of the City of Scottsdale for his work in developing the Scottsdale Cure Corridor; innovative educator Miles Orchinik, PhD of the School of Life Sciences at Arizona State University; Jack B. Jewett of the Flinn Foundation for leadership of the longest running statewide bioscience development initiative in the United States; emerging technology leaders SenesTech, Pinnacle Transplant Technologies, and Cancer Prevention Pharmaceuticals along with the 2014 Arizona Bioscience Company of the Year, Insys Therapeutics, Inc.

White Hat events continue on September 18th at the Hyatt Regency in downtown Phoenix with presentations by privately-held life science companies presenting to attending representatives of family offices, investment funds, corporate investment/business development professionals for life science oriented firms (strategic investors), granting foundations, venture capital firms, and accredited investors. In addition to great company presentations in the areas of Medical Devices, Diagnostics, Therapeutics and Health IT, White Hat includes THREE general sessions featuring panel discussions on the investment environment from the perspective of Angels, Strategic Investors, and VCs.
Presenting Companies were selected from the Rocky Mountain Southwest’s emerging innovator leaders in the fields of: Diagnostics, Therapeutics, Medical Devices and Health IT and include:

• Aviratek, LLC
• Breezing
• Calimmune, Inc.
• CardioCreate, Inc.
• Convoy Therapeutics
• DiscGenics
• Elutin Vascular Inc.
• EndoShape, Inc
• Fluonic
• Imagenonics LLC
• Iron Horse Diagnostics
• INanoBio
• Kalos Therapeutics
• Kulira Technologies
• Meditope Biosciences, Inc.
• MSDx
• NeuroRecovery Technologies, Inc.
• NuvoMed
• NuvOx Pharma
• Pediatric Bioscience, Inc
• Portable Genomics, Inc.
• MedTalk Companion (Real Phone Corp)
• Recursion Pharmaceuticals
• RiboMed Biotechnologies
• Savoy Pharmaceuticals
• SenesTech
• Skylit Medical
• Sonoran Biosciences
• T-MedRobotics
• Valley Fever Solutions
• ValveXchange
• ViroCyt
• VisionGate
• Yolia Health

bioscience

Jewett Named Arizona Bioscience Leader of the Year

jewett-sqJack B. Jewett, President & CEO of the Flinn Foundation, will be honored with the Jon W. McGarity Arizona Bioscience Leader of the Year Award by the Arizona BioIndustry Association.

“Great leaders embrace possibilities and take the steps to make them reality. Jack B. Jewett has done more than just take steps,” shared Joan Koerber-Walker, President & CEO, of the Arizona Bioindustry Association. “Thanks to his leadership and the commitment of the Flinn Foundation, Arizona has a Bioscience Roadmap that charts our statewide bioscience strategies through 2025.”

A longtime Arizona leader in health care, education, and public policy, Mr. Jewett joined the Flinn Foundation in June 2009 as President & CEO. In this role, he is responsible for all grant programs and operations of the Flinn Foundation including Arizona’s Bioscience Roadmap, which is the longest running bioscience strategic initiative of its kind in the US. Under Jewett’s leadership, Flinn has renewed its commitment and released the next generation of the Roadmap extending out until 2025.

Mr. Jewett previously served in a variety of leadership roles within the private, public, and nonprofit sectors in Arizona for more than 40 years. He held senior public policy and government relations positions with Tucson Medical Center for 13 years and served as president of Territorial Newspapers, a family-owned publishing and printing company in Tucson. He served on the Arizona Board of Regents from 1998-2006, including a term as president; and five terms in the Arizona House of Representatives, from 1983-1992, the final two years as majority whip.

A University of Arizona graduate, Mr. Jewett currently serves on the board of trustees of the Tucson-based Thomas R. Brown Foundations, is a public member of the Arizona Judicial Council, and is a member of the Greater Phoenix Leadership Council. He served on the board of directors for the National Association of Governing Boards of Universities and Colleges from 2004-13, and received its Distinguished Service Award for outstanding trusteeship for his work on “Changing Directions,” an initiative of the Arizona Board of Regents.

The Flinn Foundation is a privately endowed, philanthropic grantmaking organization established in 1965 by Dr. Robert S. and Irene P. Flinn to improve the quality of life in Arizona to benefit future generations. Today, the Foundation supports the advancement of the biosciences in Arizona, as well as three other program areas to help build Arizona’s knowledge-driven economy.

A ceremony honoring Jack B. Jewett will take place at the AZBio Awards Sept. 17 at the Phoenix Convention Center. The AZBio Awards ceremony celebrates Arizona’s leading educators, innovators and companies. Each year, AZBio honors bioindustry leaders from across the state of Arizona who are illustrative of the depth, breadth and expertise of our bioscience industry.

Past recipients of the Jon W. McGarity Arizona Bioscience Leader of the Year Award include: Linda Hunt (Dignity Health), Harry George (Solstice Capital), Robert Penny, MD, PhD (International Genomics Consortium), Patrick Soon-Shiong, MD (NantHealth), Martin L. Shultz (Pinnacle West Capital Corp.), Michael Cusanovich, Ph.D., (University of Arizona), Jonathan Thatcher (Exeter Life Sciences), John W. Murphy (Flinn Foundation), and George Poste (Arizona State University).

For registration and more information, go to www.azbio.awards.com.

medical.research

UA Researchers Earn Flinn Foundation Grant

University of Arizona researchers have been awarded a $200,000 two-year seed grant by the Flinn Foundation through its Promoting Translational Research in Precision Medicine grants program to define the pulmonary virome and the role of Cytomegalovirus (CMV) persistence in the lung. The goal of this program is to foster collaborative efforts between physician-scientists and bench researchers in order to translate findings more rapidly to actual patient treatments.

The unique research team consists of UA Associate Professor of Medicine Ken Knox, MD, who specializes in pulmonary medicine and has a strong track record in clinical/translational research; UA associate professor of immunobiology, BIO5 member and biomedical researcher, Felicia Goodrum, PhD, who is an expert in CMV persistence; and UA associate professor of ecology and evolutionary biology and BIO5 member, Matthew Sullivan, PhD, an expert in viral metagenomics.

“Translational research—moving discoveries from the lab to patient care—is a crucial element of precision, or personalized, medicine as well Arizona’s bioscience strategy,” said Jack B. Jewett, Flinn Foundation president and CEO. “This exciting collaboration among Drs. Knox, Goodrum and Sullivan is an outstanding example of a potentially groundbreaking research project that could ultimately yield great benefits to human health.”

As a privately endowed, philanthropic organization, the Flinn Foundation is committed to improving the quality of life in Arizona to benefit future generations.

The human body is home to a vast number of bacteria, viruses and fungi that collectively make up the human microbiome. Much of our microbiome does not cause disease, but rather is critically important to maintaining human health. Recent studies in humans document the enormous impact bacteria have on normal health (e.g., obesity), disease states (e.g., diabetes, gastrointestinal disorders), and even behavior. The role of viruses, by contrast, represents uncharted frontiers for study.

Persistent viruses represent emerging health threats that contribute to chronic inflammation, cellular stress and cancer risk. In addition, latent viral coexistence is just beginning to emerge in association with age-related pathologies, including atherosclerosis, immune senescence and frailty. Health costs of persistent viral infections, whether chronic or latent, can be significant.

Drs. Knox, Goodrum and Sullivan will study CMV as a model of persistent viral infection upon which questions related to how to specifically prevent lung infections can be based. Manifestations of a disease state are influenced by how background host genetic traits drive immunological responses that interact with invading viruses. By using advanced informatics to analyze metagenomic data sets from the study, the team will investigate correlations between the presence of human CMV and the background virome.

Human CMV is one of eight human herpes viruses that infects 60-90 percent of the population worldwide and, like all herpes viruses, persists in the infected host indefinitely by way of a latent infection. CMV’s primary infection of healthy individuals is typically asymptomatic and, therefore, goes completely unnoticed. When CMV is reactivated from latency to an active state of replication, there are life-threatening disease risks in immunocompromised individuals, including transplant and cancer patients. CMV infection is also the leading cause of infectious disease-related birth defects, affecting 1 percent of live births in the United States.

Dr. Janko Nikolich-Zugich, MD, PhD, Bowman Professor and head, UA Department of Immunobiology, said, “This study is extremely important and timely, as known- and yet-to-be discovered viruses are undoubtedly influencing human health and contributing to disease states.”

Fernando Martinez, MD, UA Regents’ Professor and director of both the Arizona Respiratory Center and the BIO5 Institute, agreed, adding, “Defining the viruses present in the human lung will be an important step in expanding our knowledge base of the pulmonary virome. In addition, techniques used to identify viruses hold promise for rapid diagnostics and treatments.”

Other members of the study team (photo) at UA include PhD candidates Katie Caviness and Ann Gregory, senior research scientist Bonnie Poulos, Heidi Erickson, RN, and Lance Nesbit, MS. The current study also will examine viral reservoirs in the context of lung transplant and thus is likely to have broad implications for our understanding of pulmonary immunity and rejection.

The BIO5 Institute at the University of Arizona mobilizes top researchers in agriculture, engineering, medicine, pharmacy and science to find creative solutions to humanity’s most pressing health and environmental challenges. Since 2001, this interdisciplinary approach has been an international model of how to conduct collaborative research, and has resulted in improved food crops, innovative diagnostics, devices and promising new therapies. Learn more at BIO5.org.